Expert Financial Analysis and Reporting

Investment Thesis in Brief I am recommending purchase of Chimerix at the current price. The failure of brincidofovir in the phase 3 SUPPRESS trial for prevention of cytomegalovirus infections in hematopoietic stem cell patients has caused investors to write off the company and has resulted in a depressed stock price. To illustrate, I estimate that […]

Definitions of Key Words This section defines a number of words, phrases and acronyms that I have used in this report that may be useful for investors who may not have already done extensive research on Chimerix. virus: A virus is a small, non- bacterial, infectious agent that replicates only inside the living cells of […]

Company Description Chimerix is focused on the development and commercialization of antiviral drugs. Its lead product brincidofovir is a phospholipid derivative of Gilead’s existing anti-viral agent cidofovir. The differentiating feature is a much improved side effect profile that will allow much greater use of brincidofovir for treating infections caused by double stranded viruses, notably cytomegalovirus, […]